Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26327568 | 0.79 | CA1 (0.48) | CA1CA2CA9HTTCA12 | |
| SCHEMBL14596865 | 0.77 | CA1 (0.61) | CA1CA2CA9HTTCA12 | |
| SCHEMBL28045965 | 0.77 | KDM4E (0.61) | CA1CA2CA9HTTCA12 | |
| SCHEMBL1471492 | 0.76 | SMN1; SMN2 (0.59) | HTTLMNAPOLBMAPTGAA | |
| SCHEMBL5677 | 0.76 | CA1 (0.59) | CA1CA2CA9HTTCA12 | |
| SCHEMBL31634023 | 0.74 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| Potassium Ion SCHEMBL1902294 | 0.74 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL23694531 | 0.74 | CA1 (0.53) | CA1CA2CA9HTTCA12 | |
| SCHEMBL25718115 | 0.74 | ALDH1A1 (0.37) | HTTLMNAPOLBGAAALDH1A1 | |
| SCHEMBL866410 | 0.74 | CA1 (0.71) | CA1CA2CA9HTTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929669-B | Aryl amide derivatives with antitumor activity | 中外制药株式会社 | 2024-11-29 | — | — | CN | disclosed |
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | CA1 4751/4885CA2 3972/4885CA9 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.